257 related articles for article (PubMed ID: 19598262)
21. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
22. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
[TBL] [Abstract][Full Text] [Related]
23. Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer.
Nakazato T; Kanuma T; Tamura T; Faried LS; Aoki H; Minegishi T
Int J Gynecol Cancer; 2007; 17(2):426-32. PubMed ID: 17309563
[TBL] [Abstract][Full Text] [Related]
24. Niclosamide Analogs for Treatment of Ovarian Cancer.
Walters Haygood CL; Arend RC; Gangrade A; Chettiar S; Regan N; Hassmann CJ; Li PK; Hidalgo B; Straughn JM; Buchsbaum DJ
Int J Gynecol Cancer; 2015 Oct; 25(8):1377-85. PubMed ID: 26186072
[TBL] [Abstract][Full Text] [Related]
25. Spectrin αII and βII tetramers contribute to platinum anticancer drug resistance in ovarian serous adenocarcinoma.
Maeda O; Shibata K; Hosono S; Fujiwara S; Kajiyama H; Ino K; Nawa A; Tamakoshi K; Kikkawa F
Int J Cancer; 2012 Jan; 130(1):113-21. PubMed ID: 21328338
[TBL] [Abstract][Full Text] [Related]
26. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach.
Itamochi H; Oumi N; Oishi T; Taniguchi F; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
Int J Gynecol Cancer; 2015 May; 25(4):570-6. PubMed ID: 25756405
[TBL] [Abstract][Full Text] [Related]
28. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells.
Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
[TBL] [Abstract][Full Text] [Related]
30. The Analysis of Cell Cycle-related Proteins in Ovarian Clear Cell Carcinoma Versus High-grade Serous Carcinoma.
Hazama Y; Moriya T; Sugihara M; Sano R; Shiota M; Nakamura T; Shimoya K
Int J Gynecol Pathol; 2018 Nov; 37(6):516-524. PubMed ID: 29019869
[TBL] [Abstract][Full Text] [Related]
31. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial.
Timmers PJ; Zwinderman AH; Teodorovic I; Vergote I; Trimbos JB
Int J Gynecol Cancer; 2009 Jan; 19(1):88-93. PubMed ID: 19258948
[TBL] [Abstract][Full Text] [Related]
32. Neuregulin expression, function, and signaling in human ovarian cancer cells.
Gilmour LM; Macleod KG; McCaig A; Sewell JM; Gullick WJ; Smyth JF; Langdon SP
Clin Cancer Res; 2002 Dec; 8(12):3933-42. PubMed ID: 12473609
[TBL] [Abstract][Full Text] [Related]
33. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
Han G; Gilks CB; Leung S; Ewanowich CA; Irving JA; Longacre TA; Soslow RA
Am J Surg Pathol; 2008 Jul; 32(7):955-64. PubMed ID: 18460981
[TBL] [Abstract][Full Text] [Related]
34. Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer.
Wei L; Xue T; Wang J; Chen B; Lei Y; Huang Y; Wang H; Xin X
Int J Cancer; 2009 Aug; 125(4):791-806. PubMed ID: 19391138
[TBL] [Abstract][Full Text] [Related]
35. [Study on the relationship between altered expression of annexin A4 and endometrial receptivity during the implantation window in infertile patients with endometriosis].
Jiang YL; Li B; Xing FQ; Wang F; Feng JH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):324-7. PubMed ID: 22883517
[TBL] [Abstract][Full Text] [Related]
36. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
Yoshida H; Teramae M; Yamauchi M; Fukuda T; Yasui T; Sumi T; Honda K; Ishiko O
Anticancer Res; 2013 Apr; 33(4):1409-14. PubMed ID: 23564780
[TBL] [Abstract][Full Text] [Related]
37. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
38. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
40. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].
Yan XD; Pan LY
Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
